Gene: FMO3

2328
FMOII|TMAU|dJ127D3.1
flavin containing monooxygenase 3
protein-coding
1q24.3
Ensembl:ENSG00000007933 MIM:136132 Vega:OTTHUMG00000035505 UniprotKB:P31513
NG_012690.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
11   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.317e-1 (AD)  6.447e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7051320chr1:171110559 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DCN0.745
EBF10.737
TFPI0.737
PDE5A0.729
SIX10.726
PCOLCE0.716
COL1A20.71
KLRD10.702
IL18RAP0.702
ASPN0.701

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CHRNA4-0.506
AQP11-0.501
CYP46A1-0.499
HAS1-0.492
SVOP-0.49
TENM3-0.488
RND1-0.487
DHDH-0.487
TENM2-0.483
NYAP1-0.481

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00250DapsoneSmall Molecule80-08-0Approved|InvestigationalEnzyme
DB00334OlanzapineSmall Molecule132539-06-1Approved|InvestigationalEnzyme
DB00363ClozapineSmall Molecule5786-21-0ApprovedEnzyme
DB00501CimetidineSmall Molecule51481-61-9Approved|InvestigationalEnzyme
DB00582VoriconazoleSmall Molecule137234-62-9Approved|InvestigationalEnzyme
DB00675TamoxifenSmall Molecule10540-29-1ApprovedEnzyme
DB00918AlmotriptanSmall Molecule154323-57-6Approved|InvestigationalEnzyme
DB01254DasatinibSmall Molecule302962-49-8Approved|InvestigationalEnzyme
DB05294VandetanibSmall Molecule443913-73-3ApprovedEnzyme
DB11828NeratinibSmall Molecule698387-09-6Approved|InvestigationalEnzyme
ID Drug Name Action PubMed
C0264861,2,5,6-dibenzanthracene"1,2,5,6-dibenzanthracene results in increased expression of FMO3 mRNA"26377693
C5768821-(2-trifluoromethoxyphenyl)-2-nitroethanone1-(2-trifluoromethoxyphenyl)-2-nitroethanone results in decreased expression of FMO3 protein22527513
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of FMO3 mRNA"28903501
C0388902,3,4,7,8-pentachlorodibenzofuran"2,3,4,7,8-pentachlorodibenzofuran results in decreased expression of FMO3 mRNA"21724226
C0142112,3,7,8-tetrachlorodibenzofuran"2,3,7,8-tetrachlorodibenzofuran results in decreased expression of FMO3 mRNA"21724226
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of FMO3 mRNA"28433925
C0230353,4,5,3',4'-pentachlorobiphenyl"[3,4,5,3',4'-pentachlorobiphenyl co-treated with Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA"28973532
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA]"28163111
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of FMO3 mRNA"28163111
C5716313-bromomethcathinoneFMO3 protein results in increased metabolism of 3-bromomethcathinone27320963
C0261373-hydroxyacetanilide3-hydroxyacetanilide results in decreased expression of FMO3 mRNA18544908
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of FMO3 mRNA"18648102
D000082AcetaminophenAcetaminophen results in decreased expression of FMO3 mRNA29067470
D000082AcetaminophenFMO3 protein results in decreased susceptibility to Acetaminophen24973094
D000082AcetaminophenAcetaminophen results in decreased expression of FMO3 mRNA18544908
D000082AcetaminophenAcetaminophen results in increased expression of FMO3 mRNA24126418|2497309
D000082AcetaminophenAcetaminophen results in increased expression of FMO3 protein25193093
D000082AcetaminophenNFE2L2 mutant form promotes the reaction [Acetaminophen results in increased expression of FMO3 mRNA]25193093
D000082AcetaminophenNFE2L2 mutant form promotes the reaction [Acetaminophen results in increased expression of FMO3 protein]25193093
D000082AcetaminophenAcetaminophen affects the expression of FMO3 mRNA17366322
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of FMO3 mRNA22100608|2715375
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of FMO3 gene27153756
C409045almotriptanFMO3 protein results in increased oxidation of almotriptan12642466
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of FMO3 mRNA28522335
C005277alpha-naphthyl thioureaFMO3 protein results in increased susceptibility to alpha-naphthyl thiourea12093470
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of FMO3 mRNA21298039
D000639AmitriptylineFMO3 protein results in increased metabolism of Amitriptyline27320963
C006566amitriptyline N-oxideFMO3 protein results in increased abundance of amitriptyline N-oxide27320963
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FMO3 mRNA16483693
C026987aroclor 1260[Methionine deficiency co-treated with Choline deficiency co-treated with aroclor 1260] results in increased expression of FMO3 mRNA28163111
C547126AZM551248AZM551248 results in decreased expression of FMO3 mRNA22323515
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of FMO3 mRNA26377693
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in increased expression of FMO3 mRNA26377693
D001564Benzo(a)pyreneAHR protein affects the reaction [Benzo(a)pyrene results in increased expression of FMO3 mRNA]20570689
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [TRP53 protein binds to FMO3 5' UTR]20570689
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of FMO3 mRNA19770486|2057068
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FMO3 mRNA21839799
D001591BenzydamineBenzydamine inhibits the reaction [FMO3 protein results in increased chemical synthesis of clozapine N-oxide]18809730
D001591BenzydamineFMO3 gene polymorphism affects the metabolism of Benzydamine17142560
D001591BenzydamineFMO3 protein results in increased metabolism of Benzydamine17142560
D001591BenzydamineFMO3 protein results in increased oxidation of Benzydamine21435388
D004958EstradiolEstradiol results in decreased expression of FMO3 protein12151634
D004958EstradiolEstradiol results in increased expression of FMO3 protein12151634
D047071beta-Glucansbeta-Glucans results in increased expression of FMO3 mRNA27910771
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA28628672
C006780bisphenol A[bisphenol A co-treated with retinol acetate] results in decreased expression of FMO3 mRNA28123100
C006780bisphenol A[LRAT gene mutant form affects the susceptibility to bisphenol A] which results in decreased expression of FMO3 mRNA28123100
C006780bisphenol A"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of FMO3 mRNA"28433925
C006780bisphenol Abisphenol A results in decreased expression of FMO3 mRNA25181051
C006780bisphenol Abisphenol A results in decreased expression of FMO3 mRNA26794494
D002065BuspironeBuspirone results in increased expression of FMO3 mRNA24136188
D019328Buthionine SulfoximineButhionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea]12093470
D002251Carbon TetrachlorideCarbon Tetrachloride results in decreased expression of FMO3 mRNA25193093
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of FMO3 mRNA16239168
D002737ChloropreneChloroprene results in increased expression of FMO3 mRNA23125180
D019826Cholic AcidCholic Acid results in increased expression of FMO3 mRNA17521389
D002794Choline"[3,4,5,3',4'-pentachlorobiphenyl co-treated with Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA"28973532
D002794Choline"3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA]"28163111
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with aroclor 1260] results in increased expression of FMO3 mRNA28163111
D002794Choline[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA28163111
C503589cis-9, trans-11-conjugated linoleic acid"cis-9, trans-11-conjugated linoleic acid results in decreased expression of FMO3 mRNA"17217560
D002995Clofibric AcidClofibric Acid affects the expression of FMO3 mRNA17602206
D002995Clofibric Acid[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of FMO3 mRNA17602206
D003024ClozapineFMO3 protein results in increased metabolism of Clozapine18809730|2732096
C079149clozapine N-oxideBenzydamine inhibits the reaction [FMO3 protein results in increased chemical synthesis of clozapine N-oxide]18809730
C079149clozapine N-oxideFMO3 protein results in increased abundance of clozapine N-oxide27320963
C079149clozapine N-oxideFMO3 protein results in increased chemical synthesis of clozapine N-oxide18809730
C018021cobaltous chloridecobaltous chloride results in decreased expression of FMO3 mRNA24386269
D003513CycloheximideCycloheximide results in increased expression of FMO3 mRNA20570689
D016572CyclosporineCyclosporine results in decreased expression of FMO3 mRNA20106945|2798913
D016572CyclosporineCyclosporine results in decreased expression of FMO3 mRNA21865292
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA28628672
D003907Dexamethasone[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA16054899
D003907DexamethasoneDexamethasone results in increased expression of FMO3 mRNA22733784
D003907DexamethasoneTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA]16054899
D003999Dichloroacetic AcidDichloroacetic Acid results in decreased expression of FMO3 mRNA28962523
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of FMO3 mRNA26924002
D004051Diethylhexyl Phthalate"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of FMO3 mRNA"28433925
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of FMO3 mRNA18691550
D004052DiethylnitrosamineIKBKB protein inhibits the reaction [Diethylnitrosamine results in increased expression of FMO3 mRNA]18691550
D004052DiethylnitrosamineMAPK14 protein inhibits the reaction [Diethylnitrosamine results in increased expression of FMO3 mRNA]18691550
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of FMO3 mRNA17602206
C024629dimethyl phthalatedimethyl phthalate results in decreased expression of FMO3 mRNA26924002
D004130N,N-Dimethyltryptamine"FMO3 protein results in increased metabolism of N,N-Dimethyltryptamine"27320963
D004237DiuronDiuron results in decreased expression of FMO3 mRNA25152437
C067311docetaxelFMO3 gene SNP affects the susceptibility to docetaxel23758476
D004785Environmental PollutantsEnvironmental Pollutants results in decreased expression of FMO3 mRNA20064776
D000431EthanolEthanol results in increased expression of FMO3 mRNA19167417
D000431EthanolEthanol results in increased expression of FMO3 mRNA23273579
C024565ethylene dichlorideethylene dichloride results in increased expression of FMO3 mRNA28189721
C069837fullerene C60fullerene C60 results in increased expression of FMO3 mRNA19167457
C056933fumonisin B1fumonisin B1 results in decreased expression of FMO3 mRNA16221962
C039281furanfuran results in increased methylation of FMO3 gene22079235
D005897GlafenineGlafenine results in decreased expression of FMO3 mRNA24136188
C010178heliotrineheliotrine results in decreased expression of FMO3 mRNA26100227
C002921imipramine N-oxideFMO3 protein results in increased abundance of imipramine N-oxide27320963
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA16054899
D0150561-Methyl-3-isobutylxanthineTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA]16054899
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of FMO3 mRNA24796395
C052901lemongrass oillemongrass oil affects the expression of FMO3 mRNA25976427
D008694MethamphetamineFMO3 protein results in increased metabolism of Methamphetamine27320963
C117950methamphetamine hydroxylamineFMO3 protein results in increased abundance of methamphetamine hydroxylamine27320963
D008713MethimazoleFMO3 gene polymorphism affects the metabolism of Methimazole17050781
D008713MethimazoleFMO3 protein results in increased metabolism of Methimazole17050781
D008713MethimazoleFMO3 protein results in increased oxidation of Methimazole11414682
D008713MethimazoleThioacetamide inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole]11414682
D008713Methimazoletrimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole]11414682
D008715Methionine"[3,4,5,3',4'-pentachlorobiphenyl co-treated with Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA"28973532
D008715Methionine"3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA]"28163111
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with aroclor 1260] results in increased expression of FMO3 mRNA28163111
D008715Methionine[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FMO3 mRNA28163111
D008727MethotrexateMethotrexate affects the expression of FMO3 mRNA18502557
D008748MethylcholanthreneAHR protein affects the reaction [Methylcholanthrene results in increased expression of FMO3 mRNA]20570689
D008748MethylcholanthreneMethylcholanthrene promotes the reaction [TRP53 protein binds to FMO3 5' UTR]20570689
D008748MethylcholanthreneMethylcholanthrene results in decreased expression of FMO3 mRNA25926378
D008748MethylcholanthreneMethylcholanthrene results in increased expression of FMO3 mRNA20570689|2384687
D008748MethylcholanthreneMethylcholanthrene results in increased expression of FMO3 mRNA23273579
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in increased expression of FMO3 mRNA16809437
C517284monomethyl phthalatemonomethyl phthalate affects the expression of FMO3 mRNA26924002
C568376MT19c compoundMT19c compound results in decreased expression of FMO3 mRNA21781307
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of FMO3 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of FMO3 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of FMO3 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of FMO3 mRNA"25620056
C031721naphthalenenaphthalene results in decreased expression of FMO3 mRNA18757308
D0150581-Naphthylisothiocyanate1-Naphthylisothiocyanate results in increased expression of FMO3 mRNA25193093
D0150581-Naphthylisothiocyanate1-Naphthylisothiocyanate results in increased expression of FMO3 protein25193093
D009538NicotineFMO3 protein results in increased metabolism of Nicotine12504349
C014707nitrosobenzylmethylaminenitrosobenzylmethylamine results in decreased expression of FMO3 mRNA17616710
C011521olivacineFMO3 protein affects the metabolism of olivacine analog14709624
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of FMO3 mRNA25729387
C030110oxaliplatinoxaliplatin results in increased expression of FMO3 mRNA25729387
D010464PerazineFMO3 protein results in increased oxidation of Perazine11026737
D010634PhenobarbitalPhenobarbital results in decreased expression of FMO3 mRNA23273579
D010670PhenylthioureaFMO3 protein results in increased susceptibility to Phenylthiourea12093470
C006253pirinixic acid[pirinixic acid co-treated with PPARA] results in decreased expression of FMO3 mRNA20813756
C006253pirinixic acidpirinixic acid results in decreased expression of FMO3 mRNA16221962|2081375
D011192Potassium DichromatePotassium Dichromate results in increased expression of FMO3 mRNA23608068
D011374ProgesteroneProgesterone results in increased expression of FMO3 mRNA20726854
D011763Pyrrolizidine AlkaloidsPyrrolizidine Alkaloids results in decreased expression of FMO3 mRNA26100227
D011899RanitidineFMO3 protein affects the metabolism of Ranitidine15286053
C009166retinol acetate[bisphenol A co-treated with retinol acetate] results in decreased expression of FMO3 mRNA28123100
C009166retinol acetateretinol acetate results in decreased expression of FMO3 mRNA28123100
C089730rosiglitazone[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA16054899
C089730rosiglitazoneTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA]16054899
C009238senkirkinesenkirkine results in decreased expression of FMO3 mRNA26100227
D017632Asbestos, Serpentine"Asbestos, Serpentine results in decreased expression of FMO3 mRNA"16251409|2151441
D017632Asbestos, Serpentine"SPP1 gene mutant form inhibits the reaction [Asbestos, Serpentine results in decreased expression of FMO3 mRNA]"21514415
D018038Sodium SeleniteSodium Selenite results in decreased expression of FMO3 mRNA24383545
D053260SootSoot results in decreased expression of FMO3 mRNA26551751
C075117squalestatin 1squalestatin 1 results in increased expression of FMO3 mRNA27225895
C075117squalestatin 1squalestatin 1 results in decreased expression of FMO3 mRNA27225895
D013467SulindacFMO3 gene polymorphism affects the metabolism of Sulindac17050781
D013467SulindacFMO3 gene polymorphism results in decreased metabolism of and results in increased susceptibility to Sulindac15623613
D013467SulindacFMO3 protein results in increased metabolism of Sulindac15623613|1705078
C025462sulindac sulfideFMO3 gene polymorphism affects the metabolism of sulindac sulfide17142560
C025462sulindac sulfideFMO3 protein results in increased metabolism of sulindac sulfide17142560|1755935
D013629TamoxifenTamoxifen results in decreased expression of FMO3 mRNA25123088
C030141taurine-ursodeoxycholate conjugatetaurine-ursodeoxycholate conjugate inhibits the reaction [LEP gene mutant form results in increased expression of FMO3 mRNA]21079772
C031655tauroursodeoxycholic acidtauroursodeoxycholic acid results in decreased expression of FMO3 mRNA15885361
D013739TestosteroneTestosterone results in decreased expression of FMO3 mRNA20844152|2166921
D013739TestosteroneTestosterone results in decreased expression of FMO3 protein12151634
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of FMO3 mRNA20106945
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FMO3 mRNA25703434|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FMO3 protein25703434
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin binds to AHR protein] which results in increased expression of FMO3 mRNA16214954
D013749Tetrachlorodibenzodioxin"[Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in increased expression of FMO3 mRNA"28433925
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of FMO3 mRNA25975270
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA]16054899
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to FMO3 enhancer]18765683
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to FMO3 promoter]21889950
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to FMO3 enhancer]18765683
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of FMO3 mRNA16214954|1876568
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FMO3 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of FMO3 mRNA21215274|2172422
D013853ThioacetamideThioacetamide inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole]11414682
D013890ThioureaButhionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea]12093470
D013890ThioureaFMO3 protein results in increased susceptibility to Thiourea12093470
C009495titanium dioxidetitanium dioxide results in decreased expression of FMO3 mRNA23557971|2776080
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of FMO3 mRNA25729387
C496197trans-10,cis-12-conjugated linoleic acid"trans-10,cis-12-conjugated linoleic acid results in decreased activity of FMO3 protein"17217560
C496197trans-10,cis-12-conjugated linoleic acid"trans-10,cis-12-conjugated linoleic acid results in decreased expression of FMO3 mRNA"17217560
C023336trimethylamineFMO3 gene polymorphism affects the metabolism of trimethylamine17050781|1714256
C023336trimethylamineFMO3 protein results in increased metabolism of trimethylamine12214664|1705078
C023336trimethylamineFMO3 protein results in increased oxidation of trimethylamine11414682
C023336trimethylamineFMO3 results in increased oxidation of trimethylamine16601883
C023336trimethylamineFMO3 protein results in increased oxidation of trimethylamine11414682
C023336trimethylaminetrimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole]11414682
C080163trovafloxacintrovafloxacin results in increased expression of FMO3 mRNA24136188
D014635Valproic AcidValproic Acid results in decreased methylation of FMO3 gene29154799
D014635Valproic AcidValproic Acid results in decreased expression of FMO3 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of FMO3 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004497monooxygenase activity-IBA21873635  
GO:0004499N,N-dimethylaniline monooxygenase activity-TAS-  
GO:0005515protein binding-IPI25910212  
GO:0034899trimethylamine monooxygenase activity-IEA-  
GO:0050660flavin adenine dinucleotide binding-IEA-  
GO:0050661NADP binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006805xenobiotic metabolic process-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005789endoplasmic reticulum membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
GO:0031090organelle membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-TAS9207220  
KEGG ID KEGG Term
hsa00982Drug metabolism - cytochrome P450
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1643685DiseaseTAS
R-HSA-211859Biological oxidationsTAS
R-HSA-211945Phase I - Functionalization of compoundsTAS
R-HSA-217271FMO oxidises nucleophilesTAS
R-HSA-5579019Defective FMO3 causes Trimethylaminuria (TMAU)TAS
R-HSA-5579029Metabolic disorders of biological oxidation enzymesTAS
R-HSA-5668914Diseases of metabolismTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28290528Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. (2018 Jan)Teitelbaum AMPharmacogenomics J
28413702Targeted sequencing identifies genetic polymorphisms of flavin-containing monooxygenase genes contributing to susceptibility of nicotine dependence in European American and African American. (2017 Apr)Zhang TXBrain Behav
26856397Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. (2016 Mar)Okubo MHum Psychopharmacol
25243081The Flavin-Containing Monooxygenase 3 Gene and Essential Hypertension: The Joint Effect of Polymorphism E158K and Cigarette Smoking on Disease Susceptibility. (2014)Bushueva OInt J Hypertens
19184652Molecular genetics of nicotine metabolism. (2009)Mwenifumbo JCHandb Exp Pharmacol
28583088Uncovering the transcriptomic and epigenomic landscape of nicotinic receptor genes in non-neuronal tissues. (2017 Jun 5)Zhang BBMC Genomics
8117928Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. (1993 Nov-Dec)Park SBChem Res Toxicol
12504349Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. (2003 Feb 1)Tricker ARToxicology
10509757In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles. (1999 Sep 15)Cashman JRBiochem Pharmacol
21540762Common polymorphisms in FMO1 are associated with nicotine dependence. (2011 Jul)Hinrichs ALPharmacogenet Genomics
24448396Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. (2014 Mar)Chenoweth MJPharmacogenet Genomics